Chest · 1994
The effect of exogenous surfactant therapy on lung function following cardiopulmonary bypass.
Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Macnaughton P D, Evans T W
Аннотация
OBJECTIVE: Pilot study to investigate the effect of exogenous surfactant therapy on lung function following cardiopulmonary bypass (CPB).
DESIGN: Prospective randomized controlled study.
SETTING: Adult intensive care unit of a postgraduate cardiothoracic hospital.
PATIENTS: Sixteen adult patients undergoing elective coronary artery revascularization surgery without a history of preoperative respiratory disease.
INTERVENTIONS: Artificial lung-expanding compound (ALEC, Britannia Pharmaceuticals, Crawley, UK) 3.2 g, was given via a bronchoscope 60 min after bypass in eight patients. Eight control subjects received air.
MAIN OUTCOME MEASUREMENTS: Lung function tests during IPPV (arterial blood gas tensions, Crs, FRC, TLco, KCO) were measured prior to CPB, before therapy, and at regular intervals up to 180 min afterwards.
RESULTS: The CPB caused a significant impairment of lung function in both groups with an increase in A-a gradient (+47 +/- 11 mm Hg in the ALEC group and +44 +/- 17 mm Hg in controls) and reductions in FRC (-290 +/- 121 ml in the ALEC group and -470 +/- 132 ml in controls), TLco (-1.6 +/- 0.3 ml/min/mm Hg in the ALEC group and -2.2 +/- 0.3 ml/min/mm Hg in controls), and Crs (-10 +/- 1 ml/cm H2O in the ALEC group and -21 +/- 4 ml/cm H2O in controls). The ALEC therapy did not affect A-a gradient, FRC, and Crs compared with controls. However, TLco was significantly lower in the ALEC group following therapy (120 min after treatment -0.1 +/- 0.3 ml/min/mm Hg in ALEC group and +1.0 +/- 0.3 ml/min/mm Hg in controls).
CONCLUSIONS: A single 3.2-g dose of ALEC administered as a bolus bronchoscopically does not improve lung function following CPB and may impair gas transfer.
DESIGN: Prospective randomized controlled study.
SETTING: Adult intensive care unit of a postgraduate cardiothoracic hospital.
PATIENTS: Sixteen adult patients undergoing elective coronary artery revascularization surgery without a history of preoperative respiratory disease.
INTERVENTIONS: Artificial lung-expanding compound (ALEC, Britannia Pharmaceuticals, Crawley, UK) 3.2 g, was given via a bronchoscope 60 min after bypass in eight patients. Eight control subjects received air.
MAIN OUTCOME MEASUREMENTS: Lung function tests during IPPV (arterial blood gas tensions, Crs, FRC, TLco, KCO) were measured prior to CPB, before therapy, and at regular intervals up to 180 min afterwards.
RESULTS: The CPB caused a significant impairment of lung function in both groups with an increase in A-a gradient (+47 +/- 11 mm Hg in the ALEC group and +44 +/- 17 mm Hg in controls) and reductions in FRC (-290 +/- 121 ml in the ALEC group and -470 +/- 132 ml in controls), TLco (-1.6 +/- 0.3 ml/min/mm Hg in the ALEC group and -2.2 +/- 0.3 ml/min/mm Hg in controls), and Crs (-10 +/- 1 ml/cm H2O in the ALEC group and -21 +/- 4 ml/cm H2O in controls). The ALEC therapy did not affect A-a gradient, FRC, and Crs compared with controls. However, TLco was significantly lower in the ALEC group following therapy (120 min after treatment -0.1 +/- 0.3 ml/min/mm Hg in ALEC group and +1.0 +/- 0.3 ml/min/mm Hg in controls).
CONCLUSIONS: A single 3.2-g dose of ALEC administered as a bolus bronchoscopically does not improve lung function following CPB and may impair gas transfer.